NRG Therapeutics key facts
as of Oct 2026- Developer of a drug discovery platform intended to develop therapeutic approaches to restore mitochondrial function.
- NRG Therapeutics is valued at approximately $51.9M as of Oct 2026 (last reported valuation).
- It has raised $95.0M; the latest was Later Stage VC ($66.9M) in Sep 2025.
- Notable investors include Innovate UK, British Business Bank, M Ventures, SV Health Investors, Novartis Venture Fund — 17 tracked in total.
- Status: Privately Held (backing).
NRG Therapeutics's last reported valuation, Sep 2025. Nothing priced has surfaced since.
- ·The complete investor list: 17 names
- ·Watch NRG Therapeutics: the Monday email on marks, rounds and moves
NRG Therapeutics funding rounds
No funding rounds for NRG Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs NRG Therapeutics
17+NRG Therapeutics valuation
NRG Therapeutics's last reported valuation was $51.9 million in Sep 2025. No priced round, secondary trade or fund mark has surfaced since.
NRG Therapeutics investors
17 investors are on record for NRG Therapeutics, including Innovate UK, British Business Bank, M Ventures and SV Health Investors.
About NRG Therapeutics
Developer of a drug discovery platform intended to develop therapeutic approaches to restore mitochondrial function. The company's platform aims to make novel medicines that act through the preservation of mitochondrial function for the treatment and stopping the progression of neurodegenerative diseases, enabling physicians to treat patients with chronic disorders effectively.
- Sector
- Healthcare
- HQ
- Stevenage, United Kingdom
- Founded
- 2018
- Employees
- 7
- Website
- nrgtherapeutics.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.